Use of heart failure drug restricted by FDA to 30 days

05/2/2013 | CardiovascularBusiness.com

The FDA ordered doctors to restrict the use of Otsuka Pharmaceuticals' Samsca, or tolvaptan, to 30 days or less because of potential liver damage that could result in organ transplantation or death. The treatment is indicated for clinically significant euvolemic and hypervolemic hyponatremia tied to conditions including heart failure. The agency also discourages the drug's use in patients with underlying liver disease.

View Full Article in:

CardiovascularBusiness.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX